CD22-DIDT
We have succeeded in generating an antibody to CD22 with superior internalization properties, which makes it ideal for fusion toxin applications. Fusion of this antibody with our highly potent DIDT offers the potential for a superior drug for the treatment of B cell lymphomas and leukemias.